|This Slide: #51 of 83|
Slide #51. Sangamo BioSciences — Ceregene
Sangamo BioSciences (NASDAQ:SGMO)
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. Sangamo will host a teleconference at 8:30 am ET tomorrow, Tuesday, August 27, 2013, to discuss the acquisition and provide a general business overview.
Sangamo BioSciences is a clinical stage biotechnology company focused on translating science into genomic medicines using its platform technologies in gene therapy and in vivo genome regulation. Co. is focused on these therapeutic areas: inherited metabolic diseases, central nervous system diseases and inflammatory and autoimmune diseases. Co. is evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. Under its agreement with Sanofi Genzyme, Co. is developing ST-400 and BIVV-003, ex vivo gene-edited cell therapies, for hemoglobinopathies including transfusion dependent beta thalassemia and sickle cell disease.
SGMO SEC Filing Email Alerts Service
Open the SGMO Page at The Online Investor »
Buy (3.11 out of 4)